IL-22 binding protein

IL-22 binding protein (IL-22BP), also known as interleukin-22 receptor subunit alpha-2 (IL-22RA2), is a naturally secreted, monomeric protein that functions as a soluble antagonist to interleukin-22 (IL-22)[1][3][5]. IL-22BP binds to IL-22 with higher affinity than the membrane-bound IL-22 receptor, blocking IL-22 from interacting with its cell surface receptor (IL-22R) and preventing downstream signaling. This inhibition regulates IL-22's biological activity, impacting steady-state tissue homeostasis, inflammatory responses, and cancer development. IL-22BP is being researched for its potential as an immunomodulatory therapy, particularly in diseases where IL-22 is implicated in pathology, including chronic inflammatory diseases and cancer[1][2][3][5]. Recent clinical trials are investigating the use of IL-22BP-based therapies, including mRNA-based forms, for treating advanced solid tumors[2][4]. In humans, IL-22BP is encoded by the IL22RA2 gene on chromosome 6[1][3][5].

Other names

interleukin-22 binding proteininterleukin22 binding proteininterleukin 22 binding proteinIL-22RA2IL22RA2IL 22RA2interleukin-22 receptor subunit alpha-2interleukin22 receptor subunit alpha-2interleukin 22 receptor subunit alpha-2